
Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it
Israeli life sciences investment company listed on the Tel Aviv Stock Exchange, backing biotech ventures

Listed on the Tel Aviv Stock Exchange, Clal Biotechnology Industries is an investor in life sciences based in Israel. It says it finds science-backed projects and steers them proactively toward commercial results.
The company says it supports life science ventures by finding science-backed projects and helping them grow. It holds an international portfolio of about thirteen biotechnology companies, and its team works closely with portfolio company management to turn innovative technologies into market-ready businesses. The company presents its aim as investing in ventures with proprietary solutions to unmet medical needs.
The company says it provides strategic and financial support while each venture develops its solutions, and it describes its track record of guiding ventures from early science toward the market as a core part of its approach.
MediWound develops treatments for severe burns and chronic wounds. Gamida Cell is described as a cell and immune therapy company whose lead product, omidubicel, has completed a phase III trial in hematological malignancies.
Elicio builds platform technologies that route agents to the immune cells that present antigens in lymph nodes, with potential uses in cancer and infectious diseases. Cadent Therapeutics develops drugs for neurological and psychiatric disorders, and the company notes that it has since been acquired by a large pharmaceutical group.
eXIthera is a clinical-stage biotechnology company developing small molecule inhibitors of Factor XIa, which it says could help prevent thrombosis without the bleeding risk of existing treatments. Biokine develops therapeutics for cancer, and its lead product, motixafortide, has been licensed to another company.
A separate vehicle named Cactus Acquisition Corp 1 is a special purpose acquisition company that seeks healthcare businesses with an Israeli connection. The company describes the vehicle as focused on healthcare businesses with an Israeli connection.
Clal Biotechnology Industries is an Israeli investment company focused on life sciences, with shares traded on the Tel Aviv Stock Exchange. It finds science-based projects and guides them towards commercial results.
Holdings named on its site include MediWound, which works on burn and chronic wound care, Gamida Cell, Elicio, Cadent Therapeutics, eXIthera Pharmaceuticals and Biokine Therapeutics. It also lists Cactus Acquisition Corp 1, a special purpose acquisition company targeting Israel-related healthcare businesses.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Clal Biotechnology Industries.
Similar listings buyers compare against this one.

Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

Startup accelerator and early-stage investor running intensive batches for new technology founders

Venture capital firm backing pre-seed deep technology startups in health and planetary sustainability

Venture capital firm partnering with founders from first idea through to public listing

Decentralised bandwidth network on which developers build and users run censorship-resistant VPN applications

A diversified Indian financial-services group offering credit, asset management and insurance

Prague-based pre-seed and seed investor backing technology founders from Central and Eastern Europe

Angel investment group running structured funds and co-investment deals in early-stage companies
Everything here links back to the same verified catalogue. Pick your next stop.